Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician

EMA - Emergency Medicine Australasia

Volumn 29, Issue 2, 2017, Pages 245-251

  Lomax, Anna J ^a   McNeil, Catriona ^a,b  

^a Medical Oncology   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

immune related adverse event; immunotherapy; ipilimumab; nivolumab; pembrolizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; IPILIMUMAB; LOPERAMIDE; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; PROGRAMMED DEATH 1 LIGAND 1; STEROID; THYROXINE; MONOCLONAL ANTIBODY;

ADRENAL CORTEX INSUFFICIENCY; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; BLISTER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLITIS; DEHYDRATION; DIARRHEA; DIZZINESS; EMERGENCY PHYSICIAN; FATIGUE; FLUID THERAPY; GASTROINTESTINAL TOXICITY; HEADACHE; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER TOXICITY; LYMPHOCYTE ACTIVATION; MELANOMA; NON SMALL CELL LUNG CANCER; PNEUMONIA; PROTEIN EXPRESSION; SHOCK; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THYROID DISEASE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCER; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT CANCER; VISUAL DISORDER; AUTOIMMUNITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EMERGENCY MEDICINE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; PRURITUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNITY; COLITIS; DIARRHEA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EMERGENCY MEDICINE; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PRURITUS;

EID: 85010521514     PISSN: 17426731     EISSN: 17426723     Source Type: Journal    
DOI: 10.1111/1742-6723.12718     Document Type: Article

References (17)

1. Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 2012; 366: 2517–9.
2. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614–27.
3. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015; 372: 2521–32.
4. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015; 373: 23–34.
5. Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J. Clin. Oncol. 2016; 34(Suppl): abstr 9505.
6. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363: 711–23.
7. Maio M, Grob JJ, Aamdal S et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 2015; 33: 1191–6.
8. Robert C, Ribas A, Hamid O et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J. Clin. Oncol. 2016; 34(Suppl): abstr 9503.
9. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015; 373: 1803–13.
10. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015; 373: 1627–39.
11. Plimack ER, Bellmunt J, Gupta S et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J. Clin. Oncol. 2015; 33(Suppl): abstr 4502.
12. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015; 372: 311–9.
13. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18: 733–43.
14. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 2012; 30: 2691–7.
15. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 35: 76–83.
16. Liu D, Ahmet A, Ward L et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol. 2013; 9: 30.
17. Long GV, Atkinson VG, Cebon J et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort. J. Clin. Oncol. 2016; 34(Suppl): abstr 9506.